Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Operations (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Cash from Operations for 11 consecutive years, with 2735876.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 328.47% to 2735876.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 14817110.0, a 74.08% decrease, with the full-year FY2024 number at 10910324.0, down 5.5% from a year prior.
  • Cash from Operations was 2735876.0 for Q3 2025 at Marker Therapeutics, down from 1878362.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4908502.0 in Q3 2023 to a low of 12226062.0 in Q1 2022.
  • A 5-year average of 4506172.58 and a median of 4389048.0 in 2022 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 211.84% in 2023; the steepest drop was 1139.04% in 2023.
  • Marker Therapeutics' Cash from Operations stood at 4858123.0 in 2021, then plummeted by 96.83% to 9562337.0 in 2022, then skyrocketed by 75.9% to 2304646.0 in 2023, then plummeted by 104.07% to 4703135.0 in 2024, then skyrocketed by 41.83% to 2735876.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Cash from Operations are 2735876.0 (Q3 2025), 1878362.0 (Q2 2025), and 5499737.0 (Q1 2025).